Frazier's consistent open-market buying over nine consecutive trading days signals strong conviction and a potential floor near $21. The absence of any stated change in purpose suggests this is a passive accumulation by a major insider/affiliate, not an escalation of activist demands. Watch for any future 13D amendments that might signal a shift in strategy.
Price Chart
Executive Summary
Frazier Life Sciences funds filed Amendment No. 7 to their Schedule 13D on NewAmsterdam Pharma, reporting open-market purchases of 1,048,000 ordinary shares between September 8-18, 2026 at prices ranging from $21.08 to $25.50. The filing shows continued accumulation by the Frazier group, which collectively holds approximately 18.3% of the outstanding ordinary shares (including warrants). No change in purpose or demands was disclosed.
Key Financial Metrics
Key Facts
- Frazier Life Sciences Public Fund (FLSPF) purchased 92,220 shares on 9/8/2026 at $25.1950, 119,619 shares on 9/9/2026 at $22.7696, 18,711 shares on 9/9/2026 at $23.6256, 46,110 shares on 9/9/2026 at $24.5308, 89,827 shares on 9/10/2026 at $22.3614, 2,393 shares on 9/10/2026 at $22.8579, 92,220 shares on 9/14/2026 at $22.6765, 92,220 shares on 9/15/2026 at $21.4052, 92,220 shares on 9/16/2026 at $21.1853, 46,110 shares on 9/17/2026 at $21.8749, 79,684 shares on 9/18/2026 at $21.7194, and 12,536 shares on 9/18/2026 at $22.4361.
- FLS XI purchased 1,210 shares on 9/8/2026 at $25.1950, 1,569 shares on 9/9/2026 at $22.7696, 246 shares on 9/9/2026 at $23.6256, 605 shares on 9/9/2026 at $24.5308, 1,179 shares on 9/10/2026 at $22.3614, 31 shares on 9/10/2026 at $22.8579, 1,210 shares on 9/14/2026 at $22.6765, 1,210 shares on 9/15/2026 at $21.4052, 1,210 shares on 9/16/2026 at $21.1853, 605 shares on 9/17/2026 at $21.8749, 1,046 shares on 9/18/2026 at $21.7194, and 164 shares on 9/18/2026 at $22.4361.
- FLS XII purchased 6,570 shares on 9/8/2026 at $25.1950, 8,522 shares on 9/9/2026 at $22.7696, 1,333 shares on 9/9/2026 at $23.6256, 3,285 shares on 9/9/2026 at $24.5308, 6,400 shares on 9/10/2026 at $22.3614, 170 shares on 9/10/2026 at $22.8579, 6,570 shares on 9/14/2026 at $22.6765, 6,570 shares on 9/15/2026 at $21.4052, 6,570 shares on 9/16/2026 at $21.1853, 3,285 shares on 9/17/2026 at $21.8749, 5,677 shares on 9/18/2026 at $21.7194, and 893 shares on 9/18/2026 at $22.4361.
- Frazier Life Sciences Public Fund, L.P. (FLSPF) directly holds 10,424,224 Ordinary Shares (8.7% of outstanding).
- Frazier Life Sciences X, L.P. directly holds 3,028,524 Ordinary Shares and 333,333 warrants.
- Frazier Lifesciences Sponsor LLC directly holds 3,801,000 Ordinary Shares and 167,000 warrants.
- Frazier Life Sciences XI, L.P. directly holds 1,319,923 Ordinary Shares.
- Frazier Life Sciences XII, L.P. directly holds 365,231 Ordinary Shares.
- Total aggregate beneficial ownership of the Frazier group is approximately 18.3% of the outstanding ordinary shares (including warrants).
- No change in purpose or demands was disclosed in this amendment.
Financial Impact
Frazier group purchased approximately 1,048,000 ordinary shares over 9 trading days in September 2026, with total consideration estimated at roughly $23-24 million based on weighted average prices.
Risk Factors
- No change in purpose was disclosed, so the buying may simply reflect portfolio rebalancing rather than a catalyst-driven event.
- The stock has traded down from the $25.50 high of the buying range to the low $21s, suggesting near-term selling pressure despite insider accumulation.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001231919-26-001215 |
| Document: 0001231919-26-001215-index-headers.html | 0001231919-26-001215 |
| Document: 0001231919-26-001215-index.html | 0001231919-26-001215 |
| Document: 0001231919-26-001215.txt | 0001231919-26-001215 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $23.81 $24.32 | ▲ +2.14% | ▲ +2.35% | $19.53 (−17.98%) |
Sep 22, 2026 4w ago | SC 13D/A | $22.68 $22.74 | ▲ +0.26% | ▲ +0.35% | $19.53 (−13.89%) |
Sep 15, 2026 5w ago | Insider Buy | $21.18 $21.93 | ▲ +3.54% | ▲ +2.41% | $19.53 (−7.79%) |
Aug 5, 2026 11w ago | 8-K | $27.42 $27.67 | ▲ +0.91% | ▲ +1.07% | $19.53 (−28.77%) |
Jul 24, 2026 13w ago | 8-K | $29.64 $30.22 | ▲ +1.96% | ▲ +1.94% | $19.53 (−34.11%) |
Apr 8, 2026 28w ago | Press Release | $34.01 $35.07 | ▲ +3.12% | ▲ +2.54% | $19.53 (−42.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers